Fiche publication
Date publication
juin 2025
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Robert C, Kicinski M, Dutriaux C, Routier É, Govaerts AS, Bührer E, Neidhardt EM, Durando X, Baroudjian B, Saiag P, Gaudy-Marqueste C, Ascierto PA, Arance A, Russillo M, Perrot JL, Mortier L, Aubin F, Dalle S, Grange F, Muñoz-Couselo E, Mary-Prey S, Amini-Adle M, Mansard S, Lebbe C, Funck-Brentano E, Monestier S, Eggermont AMM, Oppong F, Wijnen L, Schilling B, MandalÁ M, Lorigan P, van Akkooi ACJ
Lien Pubmed
Résumé
Current first-line treatment for patients with metastatic melanoma with BRAF or BRAF mutations includes immunotherapy with immune checkpoint inhibitors and targeted therapy; however, the optimal sequencing of these treatments is unclear. We aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors.
Mots clés
Humans, Melanoma, drug therapy, Male, Proto-Oncogene Proteins B-raf, genetics, Female, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Ipilimumab, administration & dosage, Carbamates, administration & dosage, Aged, Nivolumab, administration & dosage, Benzimidazoles, administration & dosage, Sulfonamides, administration & dosage, Mutation, Adult, Skin Neoplasms, drug therapy, Immune Checkpoint Inhibitors, administration & dosage, Progression-Free Survival
Référence
Lancet Oncol. 2025 06;26(6):781-794
